What is CagriSema? 2026 trial results and status

Mechanism and research context

An investigational fixed-dose combination of cagrilintide and semaglutide. Novo Nordisk reported additional Phase 3 topline results in September 2026; a clinical programme does not amount to marketing authorisation.

Primary source ↗

What the name describes

CagriSema is a fixed-dose combination of cagrilintide and semaglutide. It should be read as a combination programme, not as a synonym for either component alone.

Latest reported programme update

On 21 September 2026, Novo Nordisk reported topline Phase 3 results from REIMAGINE 5 and REDEFINE 9. The company described CagriSema as investigational. Topline company results are a source to read in context and do not replace regulatory assessment or peer review.

Why study names and analyses matter

REIMAGINE and REDEFINE are separate programmes with different populations, comparators, durations and analytic approaches. A headline result belongs to the specific trial and cannot be turned into a general ranking against another molecule.

Regulatory status

A Phase 3 programme and a company announcement are not marketing authorisation. This page does not provide treatment, dosing or personal-use instructions, and it does not validate a catalogue material carrying a similar molecule name.

How to assess the evidence

Check the trial, participant population, duration and comparison. Consider adverse events and discontinuations alongside the measured effect.

Results for a combination do not automatically apply to either component alone. Separate trials are not a head-to-head comparison.

What the results do not establish

Clinical findings do not establish the composition or quality of an online shop product. This profile provides no individual treatment, dosing or use instructions.